xploring Risperdal's potential value for a much broader and more diffuse clinical target, namely `behavioral disturbances in demented patients,' Dr. Paul Leber of the FDA wrote. That label, he continued, "would also encompass a range of other clinical findings, e.g., anxiety, depression, agitation, aggress